Takeda Introduces Low IgA Immunoglobulin Therapy with GAMMAGARD LIQUID ERC
Posted on
On June 30, 2025, Takeda announced that the U.S. Food and Drug Administration approved GAMMAGARD LIQUID ERC, a 10% ready-to-use liquid immunoglobulin therapy. The product is indicated as a replacement therapy for individuals aged two and older with primary immunodeficiency, and it can be administered either intravenously or subcutaneously.
Because it’s ready-to-use, it removes the need for reconstitution, potentially simplifying administration for both patients and healthcare providers .
Takeda aims to launch the product in the U.S. in 2026, with a planned rollout in the EU in 2027, where it is already approved under the name DEQSIGA®
